FMF50: a score for assessing outcome in familial Mediterranean fever.
Ozen, Seza; Demirkaya, Erkan; Duzova, Ali; Erdogan, Ozlem; Erken, Eren; Gul, Ahmet; Kasapcopur, Ozgur; Kasifoglu, Timucin; Kisacik, Bunyamin; Ozdogan, Huri; Tunca, Mehmet; Acikel, Cengizhan.
Ann Rheum Dis
; 73(5): 897-901, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24570027
[INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever.
Biologic therapy in familial Mediterranean fever.
Neonatal ulcerative colitis associated with Familial Mediterranean fever: a case report.
Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase.
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
A novel cluster of patients with Familial Mediterranean Fever (FMF) in southern Italy.
Familial Mediterranean Fever.
Chronic familial Mediterranean fever with development of secondary amyloidosis.